Stock AnalizEdwards Lifesciences Corp EW
Industrial Specialties · data as of November 13, 2026
Edwards Lifesciences Corp (EW) is a healthcare company listed in the US with a market value of about $61.6B. In the twelve months to September 30, 2026 it had revenue of $6.7B and net income of $1.0B, a net margin of 15.3%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is financial health (5/5); the weakest is value (0/5).
Key numbers: a P/E of 60.5, a price to free cash flow of 43.3, 5-year revenue growth of 7% a year, a 5-year average ROIC of 16%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 64% below the current price.
Score: 2.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.7B | $6.1B | $5.4B | $5.0B | $4.5B | $5.2B | $4.4B | $4.3B | $3.7B | $3.4B | $3.0B |
| Net income | $1.0B | $1.1B | $4.2B | $1.4B | $1.5B | $1.5B | $823M | $1.0B | $722M | $584M | $570M |
| Free cash flow | $1.4B | $1.3B | $290M | $643M | $974M | $1.4B | $647M | $928M | $688M | $833M | $528M |
| EPS (diluted) | $1.77 | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $0.90 | $0.87 |
| Net margin | 15.3% | 17.7% | 76.8% | 28.0% | 34.1% | 28.7% | 18.8% | 24.1% | 19.4% | 17.0% | 19.2% |
| ROIC | — | 9.5% | 11.6% | 15.9% | 20.1% | 22.9% | 15.3% | 21.3% | 19.0% | 15.4% | 16.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 27 analysts is $113.24, 6% above the current price; targets range from $84.00 to $126.00; the consensus rating is “Buy”; expected EPS is $3.01 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Edwards Lifesciences’s P/E ratio?
About 60.5, based on the last twelve months of diluted earnings per share (forward P/E about 33.5).
Is Edwards Lifesciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 64% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Edwards Lifesciences pay a dividend?
Not currently.
Is Edwards Lifesciences a good stock to buy?
We do not give buy or sell advice. Edwards Lifesciences scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.